Publication
Article
New and Emerging Therapies for Multiple Sclerosis and the Role of Managed Care
This supplement to The American Journal of Managed Care reviews the efficacy, safety, and limitations of current first-line therapies for multiple sclerosis (MS), describes the mechanisms of action, efficacy, and safety of 4 emerging oral therapies for MS, and discusses the potential impact of oral MS agents on patients, physicians, and managed care organizations.
Faculty
Edward J. Fox, MD, PhD
Central Texas Neurology Consultants
Round Rock, Texas
Robert J. Lipsy, PharmD, FASHP, BCPS
Clinical Assistant Professor
University of Arizona
College of Pharmacy
Tucson, Arizona
Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
University of Pennsylvania
Philadelphia, Pennsylvania
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Edward J. Fox, MD, PhD
Consultant/advisory board:
Bayer, Biogen Idec, EMD Serono, Genzyme, Pfizer, Opexa, Teva
Grants:
Biogen Idec, EMD Serono, Genzyme, Opexa, Ono, sanofi-aventis, Teva
Honoraria/lectureship/meeting and conference attendance:
Bayer, Biogen Idec, EMD Serono, Teva
Robert J. Lipsy, PharmD, FASHP, BCPS, has nothing relevant to disclose.
Clyde E. Markowitz, MD
Consultant/lectureship:
Bayer, Biogen Idec, EMD Serono, Novartis, Teva, Wyeth
Grants:
Bayer, Biogen Idec, EMD Serono, Novartis, Teva
The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.